Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children

Journal of Clinical Pharmacology

Volumn 39, Issue 5, 1999, Pages 454-461

  Loebstein, Ronen ^a   Atanackovic, Gordana ^a   Bishai, Raafat ^a   Wolpin, Jacob ^a   Khattak, Sohail ^a   Hashemi, Goli ^a   Gobrial, Marcus ^a   Baruchel, Sylvian ^a   Ito, Shinya ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; MESNA;

ADOLESCENT; AGE; ARTICLE; CHILD; CONCENTRATION RESPONSE; DRUG EFFICACY; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; LONG TERM CARE; NEPHROTOXICITY; RISK FACTOR; SOLID TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; HUMANS; IFOSFAMIDE; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS;

EID: 0032792235     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jürgens H, Treuner J, Winkler K, Gobel U: Iphosphamide in pediatric malignancies. Semin Oncol 1989;16:46-50.
2. De Kraker J: Ifosfamide in pediatric oncology. Anticancer Drugs 1991;2:339-341.
3. Goren MP, Wright RK, Horowitz ME, Pratt CB: Ifosfamide-induced subclinical tubular nephrotoxicity despite MESNA. Cancer Treat Rep 1987;71:127-130.
4. Skinner R, Pearson ADJ, Price L: The influence of age on nephrotoxicity following chemotherapy in children. Br J Cancer 1992;66(Suppl. 18):S30-S35.
5. Shore R, Greenberg M, Geary D, Koren G: Ifosfamide-induced nephrotoxicity in children. Pediatr Nephrol 1992;6:162-165.
6. Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F: Long-term follow up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol 1991;9:2177-2182.
7. Skinner R, Pearson ADJ, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW: Risk factors for ifosfamide nephrotoxocity in children. Lancet 1996;348:578-580.
8. De Schepper J, Hachimi-Idrissi S, Verboven M, Piepsz A, Otten J: Renal function abnormalities after ifosfamide treatment in children. Acta Paediatrica 1993;82(4):373-376.
9. Skinner R, Pearson ADJ, Price L, Coulthard MG, Craft AW: Nephrotoxicity after ifosfamide. Arch Dis Child 1990;65:732-738.
10. Rossi R, Gödde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jürgens H: Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994;12:159-165.
11. Rossi R, Danzebrink S, Hillebrand D, Linnenburger K, Ullrich K, Jürgens H: Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol 1994;22:27-32.
12. Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kovnar EH: Potentiation of ifosfamide neurotoxicity, hematotoxicity and tubular nephrotoxicity by prior cis-diamminedichloroplatinum therapy. Cancer Research 1987;47(5): 1457-1460.
13. Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1987;34:571-590.
14. Chantler G, Barratt TM: Laboratory evaluation. In, Holliday MA, Barratt TM, Vernier RL (eds.): Pediatric Nephrology. Baltimore, MD: Williams & Wilkins, 1985;282-285.
15. Shaw PJ, Eden T: Ifosfamide in paediatric oncology: tried but not tested? Lancet 1990;335:1022-1023.
16. Heney D, Wheeldon J, Rushworth P, Chapman C, Lewis IJ, Bailey CC: Progressive renal toxicity due to ifosfamide. Archives of Disease in Childhood 1991;66:966-970.
17. Brodehl J, Krause A, Hoyer PF: Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijovet. Pediatr Nephrol 1988;2:183-189.
18. Burghard R, Offner G, Galaske RG: Bestimmung der glomerulären filtrationsrate bei kindern aus körperlänge und senunkreatinin. Klin Pätiatr 1982;194:397-399.
19. Womer RB, Pritchard J, Barrat TM: Renal toxicity of cisplatin in children. J Pediatr 1985;106:659-663.
20. Daugaard G, Abildgaard U: Cisplatin nephrotoxicity: a review. Cancer Chemother Pharmacol 1989;25:1-9.
21. Springate J, Zamlauski-Tucker MJ, Lu H, Chan KK: Renal clearance of ifosfamide. Drug Metabolism and Disposition 1997;29(9): 1081-1082.
22. Mohrmann M, Ansorge S, Schmich U, Schonfeld B, Brandis M: Toxicity of ifosfamide and cyclophosphamide and their metabolites in renal tubular cells in culture. Pediatr Nephrol 1994;8(2):157-163.
23. 2 of ifosfamide. Cancer Chemother Pharmacol 1994;34:431-433.